Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 5/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314789 | 0.91 | CNR1 (0.41) | CNR2ALOX5GGPS1HDAC8ICMT | |
| SCHEMBL7310950 | 0.88 | CNR2 (0.40) | CNR2ALOX5GGPS1HDAC8ICMT | |
| Hydrochloric Acid SCHEMBL7309725 | 0.77 | ICMT (0.41) | ALOX5GGPS1HDAC8ICMT | |
| Hydrochloric Acid SCHEMBL7321356 | 0.74 | ICMT (0.43) | ALOX5HDAC8ICMT | |
| SCHEMBL7307874 | 0.74 | ALOX5 (0.39) | CNR2ALOX5GGPS1HDAC8ICMT | |
| SCHEMBL7307869 | 0.74 | CNR2 (0.40) | CNR2ALOX5GGPS1ICMTCAMK2D | |
| SCHEMBL7311385 | 0.70 | HTR6 (0.44) | CNR2PTGES2 | |
| SCHEMBL9334069 | 0.68 | SRD5A1 (0.60) | CNR2CREBBP | |
| SCHEMBL14876283 | 0.68 | ALDH1A1 (0.54) | CNR2PTGDR2 | |
| SCHEMBL3867265 | 0.67 | C3AR1 (0.49) | ALOX5GGPS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | CNR2 4068/4885ALOX5 2041/4885GGPS1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.